FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Amicus Therapeutics, Inc.

1 Cedar Brook Drive
Cranbury, NJ 08512
United States

Full Time Employees325

Key Executives

NameTitlePayExercisedYear Born
Mr. John F. CrowleyChairman & CEO1.72MN/A1967
Mr. Bradley L. CampbellPres, COO & Director657.99kN/A1976
Mr. William D. Baird IIIChief Financial Officer543.52k19.43k1972
Ms. Ellen S. RosenbergGen. Counsel & Corp. Sec.N/AN/A1963
Dr. Jay A. BarthChief Medical Officer782.29kN/A1964
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Corporate Governance

Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2018 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.